Skip to content

NewAmsterdam Pharma

US · NAMS #2583 by market cap Listed 1970
18.41 -1.10 -5.64%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About NewAmsterdam Pharma

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Founded
2022
CEO
Dr. Michael Harvey Davidson, M.D.
Employees
100
Headquarters
Naarden, Noord-Holland, Netherlands (the)
Fiscal year end
12-31
Website
newamsterdampharma.com

Company profile

Exchange
US
Symbol
NAMS
Market-cap rank
#2583
Listing date
1970-01-01
Market cap
2.21B
Float cap
1.51B
Shares out
119.93M
Float shares
81.84M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

NewAmsterdam Pharma discussion 0 comments

Add a comment